 |
|
|
| |
Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed With Fostemsavir (FTR)-Based Regimens
in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals With
Multidrug-Resistant (MDR) HIV-1
|
| |
| |
IDWeek 2024; October 16-19, 2024; Los Angeles, CA
Antonella Castagna,1 Natalia Gregori,2 Iacopo Marcon,2 Fangfang Du,3 Bo Li,3 Marcia Wang,3 Alftan Dyson,4 Bryn Jones,5 Manyu Prakash,5 Andrew Clark5
1Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy; 2ViiV Healthcare, Verona, Italy; 3GSK, Collegeville, PA, USA; 4ViiV Healthcare, Durham, NC, USA; 5ViiV Healthcare, Brentford, UK
Antiviral Activity of Dolutegravir in Subjects with Failure on an Integrase Inhibitor-Based Regimen: Week 24 Phase 3 Results from VIKING-3 (2) Oral
Phase 3 Assessment of Dolutegravir (DTG) 50 mg Twice Daily (BID) in HIV-1-Infected Subjects With Raltegravir (RAL) and/or Elvitegravir (EVG) Resistance in VIKING-3: Week 24 Results of All 183 Subjects Enrolled
Evolution of Integrase in Virus at Protocol-Defined Virologic Failure From the VIKING-3 Study
|
| |
|
|
|
|
|
